Page 14 - Tim Dyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message : Required fields Geneva, Switzerland, May 24, 2021 -- Addex Th https://www.globenewswire.com/Tracker?data=GKEDSALQ3NE4EtVCK9RzLXOk8Q1WB4CkSAscPRzRqf0SdKsQfRwX9gF3D5OianoM6yqhedJ0aWDLbl85uBW8pGIBsUsozfgyWuKSHEalz5Y= e https://www.globenewswire.com/Tracker?data=_w0gykO1cRWXvNInzg_3desjb1_u59TFS0A9iWd0zSqOojFGKcGUUTA-pVC88i-7tgLyk1ZFhlOA_qCsbfnT9w== rapeutics https://www.globenewswire.com/Tracker?data=Hs_rkfRwMjZ7W-Q8M7njxKHxgbDMLkKODX_R98HbsH48L3DiAk0zV907yb2MqLBez4xLV5rL_mMX9NC-yZhLsWbD6D6sL4p11kl1LT-ApNA= (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company ...

2 1 – Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will participate at the virtual Benchmark Company Healthcare House Call Conference on May 26 th, 2021 (09:00 – 16:30 EDT) Mr. Dyer will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com. About Addex Therapeutics: Addex The...

Addex Therapeutics Ltd: Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia important 2 1 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that dipraglurant was able to rescue long-term impairment of synaptic plasticity in two well validated models of dystonia. The data were published in the journal, Neuropharmacology, under the title "Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dy...

Nassau-DE, the Local Campaign Organization of the Marine Toys for Tots Foundation, recently announced the appointment of its new coordinator. James “Jim” DeMartino has been confirmed by the national Toys for Tots foundation as replacement for Bob...

Financial Summary: Income remained stable in the first quarter 2021 compared to the first quarter 2020 and related primarily to amounts received under our funded research collaboration with Indivior. R&D expenses decreased by CHF 0.8 million to CHF 2.7 million in the first quarter 2021 compared to CHF 3.6 million in the first quarter 2020, primarily due to the postponement of the start of our dipraglurant phase 2b/3 PD dyskinesia clinical trial. Research and development expenses consist primarily of costs associated with research, preclinical and clinical testing, and related staff costs. Th...